PT584 – How Psychedelics Impact the Mind: Mys...

Kenneth Tupper has spent decades working at the intersection of drug policy, public health, harm reduction, education, and psychedelics. In this episode, Joe Moore talks with Tupper about his early work with DanceSafe and drug checking, British Columbia's overdose crisis and expe ...  Afficher plus

This is an important discussion about harms, and what we should be doing about them. Josh and Roman are working on a major study at Emory University to answer some of the basic and outstanding questions we have about psychedelic risks and cases that can be challenging to recover ...  Afficher plus

In this Huberman Lab Essentials episode, my guest is Dr. Matthew Johnson, PhD, a senior researcher for the Center of Excellence for Psilocybin Research and Treatment at Sheppard Pratt’s Institute for Advanced Diagnostics and Therapeutics. We explore the science and therapeutic po ...  Afficher plus

This episode I discuss medical research on psychedelic compounds with Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine. We discuss the biology and medical clinical-trial uses of psilocybin, MDMA, ayahuasca, DMT, and L ...  Afficher plus

Psychiatrist and psychedelics and bipolar researcher Dr. Josh Woolley (University of California San Francisco), and peer researcher Amir speak on psilocybin, ketamine, and psychedelics and their links with bipolar disorder, and what the science says about psychedelics as treat ...

<span style= "font-size: 10.0pt; mso-bidi-font-family: Arial; mso-bidi-font-style: italic;"> What do the clinical trials of psilocybin and other psychedelics show in terms of efficacy and safety? How much of the benefit with psychedelic treatment is attributa ...